Steven Lefkowitz joins CorMedix board
This article was originally published in Scrip
CorMedix, a pharmaceutical company developing and commercialising therapeutic products for the prevention and treatment of cardio-renal disease, has appointed Steven Lefkowitz to its board of directors. Mr Lefkowitz is currently president of Wade Capital Corporation, a company he founded.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.